<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428140</url>
  </required_header>
  <id_info>
    <org_study_id>00051629</org_study_id>
    <nct_id>NCT02428140</nct_id>
  </id_info>
  <brief_title>Post-Embolic Rhythm Detection With Implantable Versus External Monitoring</brief_title>
  <acronym>PERDIEM</acronym>
  <official_title>Post-Embolic Rhythm Detection With Implantable Versus External Monitoring: Pilot and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Innovates Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this trial is to determine the most cost effective approach to diagnose&#xD;
      paroxysmal atrial fibrillation (PAF) following transient ischemic attack (TIA) and stroke.&#xD;
&#xD;
      A summary of the rationale for this study is as follows:&#xD;
&#xD;
        1. Recently completed randomized trials of cardiac monitoring following stroke have&#xD;
           established that PAF is more common than previously recognized in cryptogenic stroke.&#xD;
&#xD;
        2. The majority of TIA/stroke patients will have at least one potential stroke mechanism&#xD;
           identified by the time etiologic investigations completed.&#xD;
&#xD;
        3. Detecting PAF in patients with strokes with known causes (eg. lacunar and large vessel&#xD;
           atherosclerosis) is clinically important since appropriate anticoagulation for AF&#xD;
           reduces stroke recurrence in all patients with prior TIA/stroke not just cryptogenic&#xD;
           strokes.&#xD;
&#xD;
        4. There are competing technologies for evaluating cardiac rhythm and diagnosing AF but no&#xD;
           cost effectiveness data&#xD;
&#xD;
        5. The rates of PAF in strokes with known causes (SKC) have not been well characterized.&#xD;
&#xD;
      PER-DIEM is a pilot study to compare two different cardiac monitoring technologies as&#xD;
      first-line investigations to detect PAF in patients with recent stroke and TIA. The study&#xD;
      will also assess whether a pivotal trial is feasible and warranted.&#xD;
&#xD;
      The principal research questions to be addressed in this study will be:&#xD;
&#xD;
        1. Whether implantable loop recorder (ILR) plus remote monitoring will diagnose more&#xD;
           paroxysmal AF / atrial flutter and provide a better assessment of the total burden of AF&#xD;
           resulting in a greater proportion of patients started on an OAC versus the external loop&#xD;
           recorder (ELR) strategy.&#xD;
&#xD;
        2. What is the relative cost-effectiveness as a first-line investigation of long-term&#xD;
           implantable ECG (ILR) coupled with remote monitoring for 12 months compared to external&#xD;
           event-triggered ECG loop recorder (ELR) for 30 days in the diagnosis clinically&#xD;
           actionable AF in following TIA/stroke.&#xD;
&#xD;
      2) What is the feasibility, patient compliance, diagnostic accuracy and rates of AF detection&#xD;
      (&gt;30 seconds) of ILR compared to the ELR strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of clinically actionable AF</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome will be the rate of detection of an atrial arrhythmia (AF / atrial flutter) that results in initiation of additional anti-platelet or OAC therapy as per usual clinical practice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of clinically actionable AF or death</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>The first secondary outcome will be the composite of detection of an atrial arrhythmia (AF / atrial flutter) that results in initiation of additional anti-platelet or OAC therapy as per usual clinical practice or death (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>30 days, 12 months</time_frame>
    <description>Compliance with assigned therapy (accept ILR, conduct at least 80% of ELR assessments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of cardiac and non-cardiac investigations</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>Costs for all cardiac and non-cardiac investigations related to etiologic workup of index stroke / TIA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of any detected atrial fibrillation / atrial flutter.</measure>
    <time_frame>30 days, 6 months, 12, 24, 36 months</time_frame>
    <description>Total duration of any detected atrial fibrillation / atrial flutter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study related adverse events / serious adverse events.</measure>
    <time_frame>30 days, 6, 12, 24, 36 months</time_frame>
    <description>Study related adverse events / serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke / TIA, death, hemorrhagic stroke, major adverse bleeding, or death.</measure>
    <time_frame>30 days, 6, 12, 24, 36 months</time_frame>
    <description>Clinical recurrence of ischemic stroke / TIA, death, hemorrhagic stroke, major adverse bleeding, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical silent strokes, microbleeds, white matter disease</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Relationship between duration detected AF and clinically silent strokes, volume of leukoaraiosis, numbers of cerebral microbleeds</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Predictors of AF detection</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Association between baseline clinical characteristics (e.g. comorbidities, burden of supraventricular ectopy on Holter, left atrial dimension) and subsequent detection of AF</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <arm_group>
    <arm_group_label>Implanted Loop Recorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External Loop Recorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Reveal LINQ</intervention_name>
    <arm_group_label>Implanted Loop Recorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sorin Spiderflash-t</intervention_name>
    <arm_group_label>External Loop Recorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of the index event* made by a stroke specialist of an acute ischemic stroke&#xD;
             or TIA occurring within the previous 90 days. The event must be either:&#xD;
&#xD;
               1. an arterial ischemic stroke confirmed by neuroimaging; or&#xD;
&#xD;
               2. transient ischemic attack with diffusion weighted positive lesion on MRI&#xD;
&#xD;
          -  At least one 12-lead ECG has already been obtained as part of the routine clinical&#xD;
             post-stroke/TIA work-up, and no ECGs have shown any episodes of atrial fibrillation or&#xD;
             atrial flutter&#xD;
&#xD;
          -  The patient is being actively investigated for the etiology of the stroke/TIA event&#xD;
             and additional cardiac monitoring is desired to screen further for the possibility of&#xD;
             occult paroxysmal atrial fibrillation/flutter&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Informed consent from the patient&#xD;
&#xD;
          -  The patient is expected to survive at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previously documented atrial fibrillation or atrial flutter, i.e. a past history&#xD;
             of atrial fibrillation/flutter or atrial fibrillation/flutter detected on ECG, Holter,&#xD;
             or telemetry following the index stroke/TIA event (a remote history of transient&#xD;
             perioperative atrial fibrillation is not exclusionary)&#xD;
&#xD;
          -  Planned carotid endarterectomy or carotid artery stenting within 90 days&#xD;
&#xD;
          -  Any condition for which there is already an indication for long term anticoagulation&#xD;
             Pacemaker or implantable cardioverter defibrillator device&#xD;
&#xD;
          -  Work-up for stroke that has already included extended (&gt;48 hour) external ECG&#xD;
             (excluding telemetry)&#xD;
&#xD;
          -  Stroke and/or comorbid illness will prevent completion of planned follow-up&#xD;
             assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H Buck, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Community Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>etiologic investigations</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>arrhythmias</keyword>
  <keyword>embolic stroke, undetermined etiology</keyword>
  <keyword>implantable loop recorder</keyword>
  <keyword>external loop recorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 26, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

